MA22250A1 - PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINE DERIVATIVES IN POSITION 4- - Google Patents

PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINE DERIVATIVES IN POSITION 4-

Info

Publication number
MA22250A1
MA22250A1 MA22529A MA22529A MA22250A1 MA 22250 A1 MA22250 A1 MA 22250A1 MA 22529 A MA22529 A MA 22529A MA 22529 A MA22529 A MA 22529A MA 22250 A1 MA22250 A1 MA 22250A1
Authority
MA
Morocco
Prior art keywords
preparation
substituted piperidine
piperidine derivatives
derivatives
substituted
Prior art date
Application number
MA22529A
Other languages
French (fr)
Inventor
G Cooper D
H Brown T
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909017224A external-priority patent/GB9017224D0/en
Priority claimed from GB919107757A external-priority patent/GB9107757D0/en
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of MA22250A1 publication Critical patent/MA22250A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA22529A 1990-08-06 1991-08-05 PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINE DERIVATIVES IN POSITION 4- MA22250A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909017224A GB9017224D0 (en) 1990-08-06 1990-08-06 Compounds
GB919107757A GB9107757D0 (en) 1991-04-12 1991-04-12 Compounds

Publications (1)

Publication Number Publication Date
MA22250A1 true MA22250A1 (en) 1992-04-01

Family

ID=26297463

Family Applications (1)

Application Number Title Priority Date Filing Date
MA22529A MA22250A1 (en) 1990-08-06 1991-08-05 PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINE DERIVATIVES IN POSITION 4-

Country Status (15)

Country Link
EP (1) EP0542846A1 (en)
JP (1) JPH06500093A (en)
KR (1) KR930701402A (en)
CN (1) CN1061963A (en)
AP (1) AP279A (en)
AU (1) AU8327191A (en)
CA (1) CA2088491A1 (en)
IE (1) IE912759A1 (en)
IL (1) IL99073A0 (en)
MA (1) MA22250A1 (en)
MX (1) MX9100513A (en)
NZ (1) NZ239268A (en)
PT (1) PT98574A (en)
TW (1) TW267164B (en)
WO (1) WO1992002502A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
ES2135414T3 (en) * 1991-09-12 1999-11-01 Smithkline Beecham Plc 5-HT4 RECEPTOR ANTAGONISTS.
EP0629190A1 (en) * 1992-01-28 1994-12-21 Smithkline Beecham Plc Compounds as calcium channel antagonists
CA2110251A1 (en) 1992-11-30 1994-05-31 Koichi Fujimoto Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis
GB9226111D0 (en) * 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
WO1995024390A1 (en) * 1994-03-11 1995-09-14 Smithkline Beecham Plc Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
GB9411052D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Medicaments
AU4304596A (en) * 1994-12-21 1996-07-10 Neurosearch A/S A process for the preparation of substituted 4-ethyl-piperidines and an intermediate for the preparation of same
AUPN037195A0 (en) * 1995-01-03 1995-01-27 Australian Nuclear Science & Technology Organisation Piperidine-based sigma receptor ligands
JP3064425B2 (en) * 1995-09-15 2000-07-12 ノイロサーチ アクティーゼルスカブ Piperidine compounds as calcium channel blockers
FR2742051B1 (en) * 1995-12-06 1998-02-06 Synthelabo USE OF COMPOUNDS HAVING AFFINITY FOR THE (3H) IFENPRODIL BINDING SITE FOR THE MANUFACTURE OF DRUGS USEFUL IN THE PREVENTION AND TREATMENT OF NEUROPATHIES
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
AU713236B2 (en) * 1996-02-15 1999-11-25 Sankyo Company Limited Diarly alkane derivatives containing an alicyclic group, their preparation and their theraputic and prophylactic uses
CA2262686A1 (en) * 1996-08-12 1998-02-19 Mark E. Fraley Thrombin inhibitors
AU1600599A (en) 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
ATE269848T1 (en) * 1999-04-07 2004-07-15 Univ Virginia CALCIUM CHANNEL BLOCKERS AS AN ANTICANCER
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
AU9087301A (en) 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
SE0103818D0 (en) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0203828D0 (en) * 2002-12-20 2002-12-20 Astrazeneca Ab Chemical compounds
AR042628A1 (en) * 2002-12-20 2005-06-29 Astrazeneca Ab PIPERIDINE DERIVATIVES AS CCR5 RECEIVER MODULATORS
SE0301369D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
EP1641775B1 (en) 2003-07-03 2009-02-18 Euro-Celtique S.A. 2-pyridine alkyne derivatives useful for treating pain
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
SE0401656D0 (en) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
FR2872416B1 (en) * 2004-07-01 2006-09-22 Oreal USE OF PIPERIDINE DERIVATIVES TO COMBAT WRINKLES
NZ567629A (en) * 2005-09-23 2011-08-26 Ms Science Corp Piperazine derivatives useful in the treatment of discorders of the central nervous system
EP2340835A1 (en) * 2006-01-27 2011-07-06 M's Science Corporation Piperidine and piperazine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031221A (en) * 1974-06-17 1977-06-21 American Hoechst Corporation Method of treating pain and hypertension
ATE13425T1 (en) * 1981-10-15 1985-06-15 Synthelabo PIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS.
US4546105A (en) * 1984-09-04 1985-10-08 Hoechst-Roussel Pharmaceuticals Inc. Pyrrolylaminopiperidines, compositions thereof and methods of use
DE3441929A1 (en) * 1984-11-16 1986-05-28 Basf Ag, 6700 Ludwigshafen METHOD FOR PRODUCING SUBSTITUTED PIPERIDINES
DE3529994A1 (en) * 1985-08-22 1987-02-26 Hoechst Ag INDOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THE USE THEREOF
DK623586A (en) * 1985-12-27 1987-06-28 Eisai Co Ltd PIPERIDE INGREDIENTS OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS
MY104343A (en) * 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
FR2636946B1 (en) * 1988-09-23 1990-11-02 Lipha ((DIARYLMETHOXY) ALCOYL) -1 PYRROLIDINES AND PIPERIDINES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM
WO1990006303A1 (en) * 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives

Also Published As

Publication number Publication date
CN1061963A (en) 1992-06-17
MX9100513A (en) 1992-04-01
AP279A (en) 1993-08-01
PT98574A (en) 1992-06-30
IL99073A0 (en) 1992-07-15
AU8327191A (en) 1992-03-02
IE912759A1 (en) 1992-02-12
WO1992002502A1 (en) 1992-02-20
CA2088491A1 (en) 1992-02-07
NZ239268A (en) 1994-06-27
KR930701402A (en) 1993-06-11
AP9100313A0 (en) 1991-10-31
JPH06500093A (en) 1994-01-06
EP0542846A1 (en) 1993-05-26
TW267164B (en) 1996-01-01

Similar Documents

Publication Publication Date Title
MA22250A1 (en) PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINE DERIVATIVES IN POSITION 4-
MA22251A1 (en) PROCESS FOR THE PREPARATION OF PIPERIDINE DERIVATIVES SUBSTITUTED IN POSITION 3
MA22539A1 (en) PROCESS FOR THE PREPARATION OF QUINUCLIDINE DERIVATIVES
MA21808A1 (en) PROCESS FOR PRODUCING DERIVATIVES OF 2 - OXINDOLE SUBSTITUTED IN POSITION 3.
MA22563A1 (en) PROCESS FOR THE PREPARATION OF TETRAHYDROCARBAZOLE DERIVATIVES
NO180484C (en) Process for preparing substituted piperidines
PT86660A (en) PROCESS FOR PREPARING ADENOSINE 5: -CARBOXAMIDE DERIVATIVES
FR2636330B1 (en) PROCESS FOR THE PREPARATION OF MORPHINANE DERIVATIVES
MC1982A1 (en) PROCESS FOR THE PREPARATION OF DIDESOXYCITIDIN DERIVATIVES
PT87717A (en) PROCESS FOR PREPARING 2,4-THIAZOLIDINEDIONE DERIVATIVES
NO305023B1 (en) Process for the preparation of piperidine derivatives
FR2627493B1 (en) PROCESS FOR THE PREPARATION OF ISOQUINOLEIN DERIVATIVES
FI95036B (en) Method for the preparation of thieno-triazolo-diazepine derivatives
PT77197B (en) NOVEL PROCESS FOR THE PREPARATION OF SUBSTITUTED QUINUCLIDINE DERIVATIVES IN POSITION 3
MA21984A1 (en) PROCESS FOR THE PREPARATION OF QUILINONE DERIVATIVES.
EE03027B1 (en) Process for the preparation of 8-chloroquinolone derivatives
MC2108A1 (en) QUINOLEINE DERIVATIVES
FI891111A (en) Process for the preparation of 1,4-dihydropyridine derivatives
NO177146C (en) Analogous Process for Preparing New Phospholipid Derivatives
DE3464910D1 (en) PROCESS FOR PREPARING PYRIMIDINETRIONE DERIVATIVES
FI905226A0 (en) Improved process for preparing useful piperidine derivatives
FR2569698B1 (en) NEW PROCESS FOR THE PREPARATION OF DERIVATIVES OF FURO- (3,4-C) -PYRIDINE SUBSTITUTED IN POSITION 6
PT86829A (en) PROCESS FOR PREPARING THIENOTHIOPYRAN DERIVATIVES
FI963354A0 (en) Process for the preparation of piperidine derivatives
FR2661911B1 (en) PROCESS FOR THE PREPARATION OF THIENO-TRIAZOLO-DIAZEPINE DERIVATIVES.